Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.22

+2.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (8214)	4/30/2003 3:25:51 PM
From: jayhawk969	Read Replies (3) of 52153

I will post relevant information as I find it. DOVP 1. Royalty 3.5% net (best estimate) 2. Royalty/Patent expiration 2020 3. Market Cap 83.6MM 4. Shares Outstanding 14.41 MM 5. Cash 60MM 6. Three other Phase III's in progress Therefore every $100,000,000 in Indiplone sales is $.24 per share of DOVP If it hits a Billion that is is $2.40 per share. NBIX 1. Royalty 22.5% (best estimate) 2. Market Cap 1.39 B 3. Shares Outstanding 30.72 MM 4. Therefore every $100,000,000 in Indiplone sales is $.73 per share of NBIX @ 1 Billion it is $7.30 per share Ratio of revenue per share DOVP/NBIX = .33 Ration of Market Caps DOVP/NBIX = .06 DOVP 5.5x more sensitive if this analysis is correct. Comments?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next